OBJECTIVE: To investigate the effect of acetazolamide on spinocerebellar ataxia type 6 (SCA6). METHODS: Acetazolamide (250-500 mg/day) was administered orally for 88 weeks to 6 patients with SCA6, and its effect was quantitatively monitored using the Ataxia Rating Scale (ARS) and body sway analysis by stabilometry. RESULTS: During administration of acetazolamide, the ARS score and the amplitude of body sway were significantly reduced compared with before administration. However, the response became weaker after 1 year of treatment. CONCLUSION: Although this was an open trial, the results suggested that acetazolamide can temporarily reduce the severity of symptoms during the progression of SCA6.
OBJECTIVE: To investigate the effect of acetazolamide on spinocerebellar ataxia type 6 (SCA6). METHODS:Acetazolamide (250-500 mg/day) was administered orally for 88 weeks to 6 patients with SCA6, and its effect was quantitatively monitored using the Ataxia Rating Scale (ARS) and body sway analysis by stabilometry. RESULTS: During administration of acetazolamide, the ARS score and the amplitude of body sway were significantly reduced compared with before administration. However, the response became weaker after 1 year of treatment. CONCLUSION: Although this was an open trial, the results suggested that acetazolamide can temporarily reduce the severity of symptoms during the progression of SCA6.
Authors: W Ilg; A J Bastian; S Boesch; R G Burciu; P Celnik; J Claaßen; K Feil; R Kalla; I Miyai; W Nachbauer; L Schöls; M Strupp; M Synofzik; J Teufel; D Timmann Journal: Cerebellum Date: 2014-04 Impact factor: 3.847